| Serial Number | 79350059 |
| Word Mark | BEXIGNUS |
| Filing Date | Friday, August 12, 2022 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, April 30, 2024 |
| Registration Number | 7369451 |
| Registration Date | Tuesday, April 30, 2024 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 13, 2024 |
| Goods and Services | Pharmaceuticals used for the prevention and treatment of cancer, bone marrow dysfunction or suppressions, hematological malignancies, immunosystem related diseases and disorders, and diseases of chronic infections in human tissue of an individual; Medical preparations, namely, preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders; Sanitary preparations for medical purposes; Pharmaceutical preparations and substances for the treatment of cancer; Tumor suppressing agents; Antineoplastics being preparations and pharmaceutical products for preventing and treating cancer and other immunosystem related diseases and disorders; Anti-cancer preparations; Compounds for treating cancer, namely, pharmaceutical products for the prevention and treatment of cancer; Antibodies for medical use to prevent and treat inflammation and cancer growth and spread, bone marrow dysfunction or suppressions, hematological malignancies, and immunosystem related diseases and disorders; Biological preparations used for immune activation in the prevention and treatment of cancer, immunosystem related diseases and disorders, bone marrow dysfunction or suppressions, hematological malignancies, and chronic infections in human tissue of an individual; Adjuvants for medical purposes; Vaccine adjuvants; Anti-neoplastic preparations of chemical origin being pharmaceutical preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Anti-neoplastic preparations of microbial origin being pharmaceutical preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Antigens, namely, tumour antigens for medical diagnostic purposes and for anti-cancer preparations; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical use, namely, biological preparations for the treatment of conditions with poor production of hematopoietic stem cells; Biotechnological preparations for medical use, namely, biological preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Immunomodulators, namely, pharmaceutical preparations for restoring and modifying the immune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations for the prevention of disorders of the immune system; Serotherapeutic medicines, namely, pharmaceutical preparations used for immune activation in the treatment of cancer and in the treatment of diseases of chronic infections in human tissue of an individual; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for use in hematology |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, September 19, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Faron Pharmaceuticals Oy |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 09 - Joint Stock Company |
| Address | FI |
| Party Name | Faron Pharmaceuticals Oy |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 09 - Joint Stock Company |
| Address | FI |
| Party Name | Faron Pharmaceuticals Oy |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 09 - Joint Stock Company |
| Address | FI |
| Event Date | Event Description |
| Friday, September 16, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, September 19, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, September 23, 2022 | APPLICATION FILING RECEIPT MAILED |
| Thursday, June 1, 2023 | ASSIGNED TO EXAMINER |
| Thursday, June 1, 2023 | NON-FINAL ACTION WRITTEN |
| Friday, June 2, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Saturday, July 8, 2023 | REFUSAL PROCESSED BY MPU |
| Saturday, July 8, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, August 1, 2023 | REFUSAL PROCESSED BY IB |
| Friday, December 29, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, December 29, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, December 29, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, January 5, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, January 24, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, January 24, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, January 24, 2024 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Tuesday, February 13, 2024 | PUBLISHED FOR OPPOSITION |
| Tuesday, February 13, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, February 21, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Monday, March 11, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Tuesday, April 30, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, April 30, 2024 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, April 30, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, July 30, 2024 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Wednesday, February 14, 2024 | NOTIFICATION PROCESSED BY IB |
| Wednesday, February 21, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |